AU548996B2 - Tetrahydro-2h-pyran-2-one derivatives - Google Patents

Tetrahydro-2h-pyran-2-one derivatives

Info

Publication number
AU548996B2
AU548996B2 AU66573/81A AU6657381A AU548996B2 AU 548996 B2 AU548996 B2 AU 548996B2 AU 66573/81 A AU66573/81 A AU 66573/81A AU 6657381 A AU6657381 A AU 6657381A AU 548996 B2 AU548996 B2 AU 548996B2
Authority
AU
Australia
Prior art keywords
pyran
tetrahydro
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU66573/81A
Other languages
English (en)
Other versions
AU6657381A (en
Inventor
William F. Hoffman
Robert L. Smith
Alvin K. Willard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU548996(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/175,232 external-priority patent/US4293496A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU6657381A publication Critical patent/AU6657381A/en
Application granted granted Critical
Publication of AU548996B2 publication Critical patent/AU548996B2/en
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AU66573/81A 1980-02-04 1981-01-23 Tetrahydro-2h-pyran-2-one derivatives Expired AU548996B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11805180A 1980-02-04 1980-02-04
US11804980A 1980-02-04 1980-02-04
US118049 1980-02-04
US118051 1980-02-04
US17546080A 1980-08-05 1980-08-05
US175232 1980-08-05
US06/175,232 US4293496A (en) 1980-02-04 1980-08-05 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones
US175460 1988-04-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU89179/82A Addition AU8917982A (en) 1982-10-06 1982-10-06 Anti hypercholesterolemic compounds

Publications (2)

Publication Number Publication Date
AU6657381A AU6657381A (en) 1981-08-13
AU548996B2 true AU548996B2 (en) 1986-01-09

Family

ID=27494171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66573/81A Expired AU548996B2 (en) 1980-02-04 1981-01-23 Tetrahydro-2h-pyran-2-one derivatives

Country Status (22)

Country Link
EP (1) EP0033538B1 (en:Method)
AU (1) AU548996B2 (en:Method)
CA (1) CA1199322A (en:Method)
CY (1) CY1404A (en:Method)
DD (1) DD155989A5 (en:Method)
DE (1) DE3173042D1 (en:Method)
DK (1) DK157292C (en:Method)
ES (1) ES499079A0 (en:Method)
FI (1) FI78082C (en:Method)
GR (1) GR74798B (en:Method)
HK (1) HK16488A (en:Method)
IE (1) IE51478B1 (en:Method)
IL (1) IL62044A (en:Method)
MA (1) MA19054A1 (en:Method)
MY (1) MY8700745A (en:Method)
NL (1) NL930009I2 (en:Method)
NO (2) NO154229C (en:Method)
NZ (1) NZ196172A (en:Method)
PT (1) PT72441B (en:Method)
RO (1) RO82367B (en:Method)
SG (1) SG61087G (en:Method)
YU (1) YU28181A (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631909B2 (en) * 1989-07-04 1992-12-10 British Bio-Technology Limited 6-(hydronaphtyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2h- pyran-2-ones and the corresponding hydroxy acids

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692381B2 (ja) * 1980-03-31 1994-11-16 三共株式会社 Ｍｂ−５３０ａ誘導体
US4343814A (en) * 1980-11-17 1982-08-10 Merck & Co., Inc. Hypocholesterolemic fermentation products
US4432996A (en) * 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
EP0094443A1 (en) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same
US4503072A (en) * 1982-12-22 1985-03-05 Merck & Co., Inc. Antihypercholesterolemic compounds
CA1268473A (en) * 1983-01-24 1990-05-01 Paul L. Anderson Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
EP0137445B1 (en) * 1983-10-11 1990-01-03 Merck & Co. Inc. Process for c-methylation of 2-methylbutyrates
EP0137444B1 (en) * 1983-10-11 1990-01-31 Merck & Co. Inc. Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-Decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
US4668699A (en) * 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
AU7271696A (en) * 1995-12-06 1997-06-27 Antibiotic Co Method of production of lovastatin
CA2185961A1 (en) 1996-09-19 1998-03-20 K.S. Keshava Murthy Process for producing simvastatin
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
SI9800057A (sl) * 1998-02-26 1999-08-31 Krka, Tovarna Zdravil, D.D. Postopek za pripravo simvastatina in njegovih derivatov
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
ATE241386T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren
EP1340508A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
PT1140190E (pt) 1998-12-23 2003-02-28 Searle Llc Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
EP1140186B1 (en) 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
ES2203239T3 (es) 1998-12-23 2004-04-01 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de agentes secuestrantes de acidos biliares para indicaciones cardiovasculares.
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
WO2000038727A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
HUP0302929A3 (en) 2000-09-07 2004-10-28 Kaneka Corp Methods for crystallization of hydroxycarboxylic acids
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
SI21187A (sl) 2002-03-26 2003-10-31 Krka, Tovarna Zdravil D.D., Novo Mesto Postopek za pripravo 4-oksitetrahidropiran-2-onov
KR20040092790A (ko) * 2003-04-29 2004-11-04 씨제이 주식회사 심바스타틴 중간체 제조방법
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
WO2009013764A2 (en) * 2007-07-24 2009-01-29 Jubilant Organosys Limited Process for producing 6(r)-[2-(8'(s)-2 ',2 '-dimethylbutyryloxy-2'(s),6'(r)-dimethyl-1,2,6,7', 8',8a'(r)- hexahydronaphthyl-l'(s))ethyl]-4(r)-hydroxy-3,4,5,6- tetrahydro-2h-pyran-2-one
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
ES2343049B1 (es) 2008-10-15 2011-06-10 Neuron Biopharma, S.A. Biosintesis de derivados de monacolina j.
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2241561A1 (en) * 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
CA2865796A1 (en) 2011-12-29 2013-07-04 Trustees Of Tufts College Functionalization of biomaterials to control regeneration and inflammation responses
CA2875096A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049495A (en) * 1974-06-07 1977-09-20 Sankyo Company Limited Physiologically active substances and fermentative process for producing the same
JPS5612114B2 (en:Method) * 1974-06-07 1981-03-18
DE2748825C2 (de) 1976-11-02 1986-11-27 Sankyo Co., Ltd., Tokio/Tokyo Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
JPS6026094B2 (ja) 1978-07-04 1985-06-21 三共株式会社 テトラヒドロｍｌ↓−２３６ｂおよびその誘導体並びにそれを有効成分とする高脂血症治療剤
JPS5925599B2 (ja) * 1979-02-20 1984-06-19 三共株式会社 新生理活性物質モナコリンｋおよびその製造法
IL60219A (en) * 1979-06-15 1985-05-31 Merck & Co Inc Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
PT72394B (en) 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631909B2 (en) * 1989-07-04 1992-12-10 British Bio-Technology Limited 6-(hydronaphtyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2h- pyran-2-ones and the corresponding hydroxy acids

Also Published As

Publication number Publication date
GR74798B (en:Method) 1984-07-12
AU6657381A (en) 1981-08-13
HK16488A (en) 1988-03-11
PT72441B (pt) 1984-08-01
RO82367A (ro) 1984-02-21
EP0033538A3 (en) 1982-02-24
NO1994001I1 (no) 1994-07-01
NL930009I1 (nl) 1993-04-01
NZ196172A (en) 1985-01-31
MA19054A1 (fr) 1981-10-01
FI810287L (fi) 1981-08-05
NL930009I2 (nl) 1993-09-16
RO82367B (ro) 1984-02-28
IE810204L (en) 1981-08-04
DK46181A (da) 1981-08-05
EP0033538B1 (en) 1985-11-27
NO154229B (no) 1986-05-05
DE3173042D1 (en) 1986-01-09
EP0033538A2 (en) 1981-08-12
NO810358L (no) 1981-08-05
IL62044A0 (en) 1981-03-31
CY1404A (en) 1988-04-22
MY8700745A (en) 1987-12-31
ES8609296A1 (es) 1985-10-16
DD155989A5 (de) 1982-07-21
PT72441A (pt) 1981-03-01
IE51478B1 (en) 1987-01-07
FI78082B (fi) 1989-02-28
DK157292B (da) 1989-12-04
NO154229C (no) 1986-08-13
DK157292C (da) 1990-05-07
IL62044A (en) 1987-03-31
CA1199322A (en) 1986-01-14
YU28181A (en) 1983-10-31
ES499079A0 (es) 1985-10-16
SG61087G (en) 1987-10-23
FI78082C (fi) 1989-06-12

Similar Documents

Publication Publication Date Title
AU548996B2 (en) Tetrahydro-2h-pyran-2-one derivatives
AU542623B2 (en) 1-hydroxyethyl-azole derivatives
AU557689B2 (en) 1-sulfo-2-oxoazetidine derivatives
AU544723B2 (en) Imidazolylpropanol derivatives
AU7551681A (en) 3-aryl-5-isothiazole derivatives
AU540898B2 (en) 17-disubstituted-androst-4-en-3-one derivatives
AU534878B2 (en) Amino-saccharide derivatives
AU544527B2 (en) Bis-carboxamide derivatives
AU554360B2 (en) S-triazinyl-aminofluorescein derivatives
AU545357B2 (en) Triazolo-benzodiazepine derivatives
AU551238B2 (en) 1-hydroxy-2 -fluorocholecalciferol derivatives
AU544907B2 (en) Isonicotinanilide derivatives
AU538505B2 (en) Phenoxy-aminopropanol derivatives
AU540239B2 (en) 2-guanidinothiazole derivatives
AU539443B2 (en) Phenoxybutyltriazole derivatives
AU537942B2 (en) Substituted thiophine derivatives
AU7596281A (en) Sydnonimined derivatives
AU6898281A (en) Biphenylyl-azolylethane derivatives
AU7486481A (en) N-oxyamide derivatives
AU7494381A (en) Fluorinated-1-azolyl-butane derivatives
AU526941B2 (en) Pyrazole-substituted oximino-cyano-acetamide derivatives
AU6826781A (en) Steroid-spiro-oxathiazolidine derivatives
AU7776681A (en) Bisaminomethyl-anthraquinone derivatives
AU541157B2 (en) Pyridinethiolato-aluminium derivatives
AU539662B2 (en) Cycloheptindolol derivatives

Legal Events

Date Code Title Description
NDB Extension of term for standard patent granted (sect.76)

Free format text: 19/07/2005